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Extracellular vesicles (EVs) are membrane-bound particles secreted by almost all cell types.
They are classified depending on their biogenesis and size into exosomes and microvesi-
cles or according to their cell origin. EVs play a role in cell-to-cell communication, including
contact-free cell synapsis, carrying active membrane proteins, lipids, and genetic material
both inside the particle and on their surface.They have been related to several physiological
and pathological conditions. In particular, increasing concentrations of EVs have been found
in many autoimmune diseases including multiple sclerosis (MS). MS is a central nervous
system (CNS) demyelinating disease characterized by relapsing of symptoms followed by
periods of remission. Close interaction between endothelial cells, leukocytes, monocytes,
and cells from CNS is crucial for the development of MS.This review summarizes the patho-
logical role of EVs in MS and the relationship of EVs with clinical characteristics, therapy,
and biomarkers of the disease.
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WHAT ARE EXTRACELLULAR VESICLES?
Extracellular vesicles (EVs) are membrane-bound particles com-
ing from inside a cell or formed directly from its membrane,
and excreted to the extracellular medium, that carry information
whose function is cell-to-cell communication without direct con-
tact. They play a role in physiological and pathological conditions,
being released during cell activation, stress, and apoptosis. Specifi-
cally, these vesicles carry proteins, lipids, and genetic materials such
as DNA, RNA, and miRNA, producing genotypic (Waldenström
et al., 2012) and phenotypic (van der Vos et al., 2011) modifica-
tions in the recipient cell. This is facilitated by the receptors on the
surface of the EV membrane that allow the target cell to identify
the vesicles and interact with them (Choudhuri et al., 2014).
EVs CLASSIFICATION
BIOGENESIS
Though there are several ways of classifying EVs, the main division
in nomenclature is based on biogenesis. Those formed inside mul-
tivesicular bodies and released extracellularly upon fusion of these
bodies with the plasma membrane are called exosomes (Théry
et al., 2009). Their main characteristic is to have a uniform size
of between 30 and 150 nm, making them the smallest EVs. On
the other hand, those known as microparticles (MP), microvesi-
cles (MV), or ectosomes come from the modification of the cell
membrane after external or internal stimuli, leading to a softening
of the membrane-adjacent structure and allowing evagination and
Abbreviations: BBB, blood–brain barrier; CNS, central nervous system;
CSF, cerebrospinal fluid; EAE, experimental autoimmune encephalitis; EEV,
endothelial-derived EV; EV, extracellular vesicle; LEV, leukocyte-derived EV; MEV,
monocyte/microglia-derived EV; MP, microparticle; MS, multiple sclerosis; MV,
microvesicle; PEV, platelet-derived EV.
vesicle formation followed by fission on the connecting membrane
stalks until their full detachment. These MV/MPs vary greatly in
size, ranging from 0.3 to 1µm in diameter (Mause and Weber,
2010; Frey and Gaipl, 2011; Lai and Breakefield, 2012). However,
the current trend is to call the entire set EVs, the term used by
the newly formed International Society of Extracellular Vesicles
(Witwer et al., 2013).
In this review, we follow this trend, using the term EVs to refer to
all vesicles; we note, however, that specifically in multiple sclerosis
(MS) related-research most studies refer to them as MPs or MVs.
CELL ORIGIN
Extracellular vesicles have been also classified as a function of
their cell origin depending on the parental cell from which they
arose, so far the most studied being those obtained from cir-
culating cells in peripheral blood. Each cell has characteristic
markers on its membrane enabling subsequent identification of
the EV, e.g., as erythrocyte-, leukocyte-, platelet-, endothelial-,
or monocyte-derived. Further, studies focusing on central ner-
vous system (CNS)-derived EVs have described neural stem cell-,
neuron-, astrocyte-, microglia-, and oligodendrocyte-derived vesi-
cles (Lai and Breakefield, 2012) with the goal of finding markers
that may reflect CNS status, since they can be detected remote
from the site of release after cell activation.
TECHNIQUES FOR STUDYING EVs
The study of EVs is not straightforward, particularly with respect
to isolation and characterization due to their small size and the low
concentrations found in human fluids. Further, although efforts
have been made to unify criteria in EV research (Robert et al., 2008;
Dey-Hazra et al., 2010; Lacroix et al., 2012a; Witwer et al., 2013),
they are not yet clearly established, making it difficult to compare
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studies. Differences derived from centrifugation protocols, fluo-
rochrome labeling, and gating strategies represent as yet unsolved
barriers to standardization. Nevertheless, the most widely used
techniques can be summarized as follows.
ISOLATION
The main approach that has been used for isolating EVs from
human fluids or culture media supernatants is a series of sequential
centrifugation steps. Different purities are obtained depending on
the number of steps completed. Briefly, a first centrifugation step
at a low velocity (200–300 g) separates cells from EV-containing
fluid, which can be further purified or directly pelleted. For a fur-
ther purification, a second centrifugation must be carried out (at
2,000–10,000× g, depending on the fluid or EV fraction required).
Otherwise, EVs can be directly pelleted from the first supernatant
(centrifuging at forces of 10,000 up to 100,000× g ). Though
there are many variations among authors, the first approach to
EV analysis is usually based on the aforementioned steps. As
an alternative protocol to obtain a more pure EV fraction, a
sucrose gradient can be combined with one of the centrifugation
steps.
Another isolation technique is polymeric precipitation (e.g.,
Exoquick, System Biosciences, CA, USA). The main advantage of
this approach is rapid sample processing. However, the low purity
obtained and mixing of different EV subsets make results difficult
to interpret.
The extraction of EVs by passing a sample through filters is a
cheap and easy method that can be applied alone or combined
with centrifugation. There is, however, a risk of contamination
with particles other than EVs of the same size.
CHARACTERIZATION
Flow cytometry is the technique most widely employed for study-
ing EVs (including in MS research) to the possibility of using
multiple parameters to identify the same vesicle. It is a power-
ful characterization tool, the process is rapid and the results can
be quantified. Its main limitation is poor discrimination under
0.5µm. However, new high-resolution cytometers can detect
particles as small as 0.2–0.3µm.
Recently, two novel tools appeared on the market created to
characterize nanoparticles in size and concentration with a high
resolution. They measure particles based on tunable resistive pulse
sensing (qNANO, IZON Science, New Zealand) and Brownian
motion of the particle with nanoparticle tracking analysis soft-
ware (NS500 and NS300, Nanosight, UK). The simple and user-
friendly operation and powerful measurements provided by these
instruments herald a new era in the analysis of EVs.
Electron microscopy is usually performed in combination with
flow cytometry to provide direct evidence of the presence of EVs,
and it provides what is arguably the highest quality morphologi-
cal information (Figure 1). On the other hand, the expensive and
complex processing of samples limits its use.
Fluorescence microscopy is normally used to analyze EV func-
tion in vitro, as well as to localize EV in tissues and budding process.
In particular, confocal microscopy is widely used in EV research.
In addition, enzyme-linked immunosorbent and Western blot
assays have also been employed for analysis of EVs but are less
FIGURE 1 | Electron microscopy image of EVs. An electron microscopy
image of an EV cluster obtained from peripheral blood. Note the rounded
shape and cell membrane-like appearance of EV surfaces.
extensively used due to the poor characterization they provide
and that they are difficult to quantify, respectively.
Notably, next-generation sequencing techniques are currently
expanding to the field of EVs, specifically in the attempt to
characterize their genetic cargo.
EVs IN NEUROSCIENCE
Vesicle secretion and the transfer of material carried within them
in the CNS under physiological conditions were described many
decades ago (de Robertis and Bennett, 1954). The classic example
was the presence of vesicles in the neuronal synapses (de Rober-
tis and Bennett, 1955). However, the mechanisms involved and
modulation thereof by astrocytes, through the release of vesicles
into the synaptic space, have only been properly understood in
recent years (Antonucci et al., 2012). Vesicles have been impli-
cated not only in the propagation of signals, but also in control-
ling neurogenesis with exosomes being involved in the regulation
of myelin membrane biogenesis (Marzesco et al., 2005; Bakhti
et al., 2011) and repairing damaged neurons (Court et al., 2011).
Moreover, a recent study identified a new mechanism of regula-
tion of the axonal integrity mediated by oligodendrocyte-derived
EVs transferred to neurons (Frühbeis et al., 2013). It has been
observed that EVs are released by neural cells, oligodendrocytes,
neurons, microglia, astrocytes in the brain, and Schwann cells in
the peripheral nervous system (reviewed by Lai and Breakefield,
2012; Frühbeis et al., 2012). All this implies that EVs perform func-
tions necessary for growth and normal functioning of the nervous
system.
In addition, EVs are involved in processes of CNS diseases car-
rying specific pathological cargo or performing functions that
produce potential damage (Lai and Breakefield, 2012). Several
studies have found variations in the number and function of cir-
culating EVs in peripheral blood in diseases including Alzheimer’s
disease, dementia, epilepsy, stroke, traumatic brain injury, malaria,
and tumors (mainly glioblastoma), among others (reviewed by
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Lai and Breakefield, 2012; Doeuvre et al., 2009). To explore these
functions, most studies expose primary cell cultures to suspen-
sions of EVs analyzing the effects produced by EV in the cells such
as morphological changes, fusion processes, induction of prolifer-
ation, and apoptosis. Another approach is to analyze EVs derived
directly from human fluids. For this, peripheral blood and CSF are
the most frequently studied samples. On the other hand, few stud-
ies have explored whether variations in EVs in CSF directly reflect
the pathophysiology of the CNS (Morel et al., 2008; Huang et al.,
2009; Street et al., 2012; Verderio et al., 2012; Mobarrez et al., 2013;
Patz et al., 2013; Joshi et al., 2014) and only a couple of them have
examined EVs derived from brain cells obtained from the CSF as a
surrogate marker for what occurs in the CNS (Verderio et al., 2012;
Joshi et al., 2014). Above all, it has not yet been elucidated whether
EVs are able to migrate from the blood across the blood–brain bar-
rier (BBB) into the CNS (or not) and vice versa (Smalheiser, 2009).
More studies are required to provide evidence on whether there
is an EV-mediated communication channel between the nervous
and the cardiovascular systems.
MULTIPLE SCLEROSIS (MS) AS A NEUROIMMUNE DISEASE
Multiple sclerosis is a chronic autoimmune disease affecting the
CNS, the cause of which remains elusive. It is, however, established
that the pathogenesis of the disease involves genetic, environmen-
tal, and immune components (Bernard and Kerlero de Rosbo,
1992). There are different clinical forms, but the most prevalent
is relapsing–remitting MS, characterized by outbreaks of symp-
toms lasting 1–3 weeks called relapses, followed by a recovery
phase. During relapses, multiple areas of demyelination emerge,
this being the main pathological feature of the disease. Immune
activation involved in the onset of the disease causes a release of
proinflammatory cytokines (TNF, IL1-beta, IFN-gamma) plus a
proliferation of leukocytes, monocytes, and platelets (Martino and
Hartung, 1999). At the same time, endothelial dysfunction of the
BBB affects its permeability, facilitating the activation, adhesion,
and transendothelial migration of monocytes and T-lymphocytes
into the CNS (Minagar et al., 2012). Cytokines and chemokines
released at the site of a lesion recruit glial cells, macrophages,
and lymphocytes perpetuating the immune activation leading to
a chronic inflammatory state (McFarland and Martin, 2007). Cur-
rently, the diagnosis of MS is based on the 2010 revised McDonald
criteria (Polman et al., 2011) including careful clinical evaluation
supported by MRI findings and oligoclonal banding in the CSF,
the main complementary tools. The treatment of MS has under-
gone a revolution with the advent of IFN-beta as a treatment in the
1980s and more recently with the new immunomodulator drugs,
such as natalizumab and fingolimod.
Several studies summarized in this review suggest EVs are active
players in the pathophysiological development of this disease.
More specifically, higher numbers of EVs have been observed in
MS patients than in healthy controls and a role for EVs has been
proposed in inflammatory progression and lesion repair. Because
of this, they could serve as new biomarkers of disease development
and targets for future treatments.
We will discuss these issues in the following sections. In Table 1
we summarize the origins and makers used for EVs reported.
IMMUNE ROLES OF EVs IN MS
One of the necessary processes for the establishment of MS is the
transendothelial migration of leukocytes into the CNS through
Table 1 | Cellular origins of extracellular vesicles (EVs) in multiple sclerosis research.
EV origin Marker Sample Technique Reference
Endothelial CD31+/CD42− PPP and MVEC FC Minagar et al. (2001)
WB and MVEC FC Jy et al. (2004), Jimenez et al. (2005)
CD51 PPP and MVEC FC Minagar et al. (2001)
CD54 WB and MVEC FC Jy et al. (2004), Jimenez et al. (2005)
CD106 WB and MVEC FC Jy et al. (2004)
CD62E WB and MVEC FC Jy et al. (2004), Jimenez et al. (2005)
CD146 PPP FC Lowery-Nordberg et al. (2011)
Platelet CD61 PFP FC Sáenz-Cuesta et al. (2014)
CD41 PPP FC Sheremata et al. (2008)
Leukocyte CD45 PFP FC Sáenz-Cuesta et al. (2014)
Monocyte CD14 PFP FC Sáenz-Cuesta et al. (2014)
Astrocyte GFAP CSF FM/WestB Verderio et al. (2012)
Neuronal SNAP-25 CSF FM/WestB Verderio et al. (2012)
Oligodendrocyte MBP CSF FM/WestB Verderio et al. (2012)
Microglia/macrophage IB4 CSF FM/FC/EM Verderio et al. (2012)
GENERAL MARKERS
Exosomes CD63 PFP WestB Williams et al. (2013), Gatson et al. (2011)
Microvesicles AnV CSF FC Verderio et al. (2012)
EM, electron microscopy (immunogold); PPP, platelet poor plasma; PFP, platelet free plasma; WB, whole blood; WestB, Western blot; CSF, cerebrospinal fluid; FC,
flow cytometry; FM, fluorescence microscopy; MVEC, microvascular endothelial cell culture.
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the BBB. This migration is favored by a weakening of the bar-
rier. The fact that this mechanism is crucial to the pathogenesis
of MS is demonstrated by the benefits observed with natalizumab,
which blocks the entry of leukocytes into the CNS (del Pilar Mar-
tin et al., 2008). Proinflammatory cytokines such as TNF-alpha,
IFN-gamma, and IL1-beta released by inflammatory cells mediate
the breaching of the BBB by the upregulation of the expression of
adhesion molecules (VCAM-1, E-selectin, and PECAM-1) (Dore-
Duffy et al., 1995), the loss of junctional integrity (Minagar et al.,
2003), and the release of endothelial-derived EVs (EEVs) (Mina-
gar et al., 2001). EEVs from the endothelial cells of BBB and
other EVs shed from surrounding cells [leukocytes (LEV), platelets
(PEV), microglia (MEV), and astrocytes] are vectors of numerous
agents carried inside these vesicles or bound to their plasma mem-
brane. The presence of metalloproteinases in EV cargo suggests
that they may participate in the degradation of the extracellular
matrix involved in BBB disruption (Sbai et al., 2010; Lacroix et al.,
2012b). Moreover, caspase 1 carried by EVs shed by monocytes
and microglia has been shown to regulate proteolytic activity of
metalloproteases on endothelial cells (Bianco et al., 2005; Sarkar
et al., 2009).
Minagar et al. (2001) hypothesized that plasma from MS
patients contains factors that can induce endothelial activation,
as suggested by the release into circulation of CD31+ EEVs from
microvascular endothelial cell culture (MVEC) – a BBB model –
treated with plasma from patients both in exacerbation and remis-
sion. After this pivotal study, Jy et al. (2004) demonstrated that
EEVs found in plasma are able to interact and form complex with
monocytes and induce their activation. These activated monocytes
express Mac-1 integrin, which is an ICAM-1 receptor. The union
of Mac-1 of monocytes with ICAM-1 of endothelial cells plays
an important role in the transendothelial migration of inflam-
matory cells. Moreover, activated T cells release EVs containing
the chemokine CCL5 and arachidonic acid responsible for pro-
moting recruitment of monocytes and upregulating ICAM-1 in
endothelial cells and LFA1 and Mac-1 in monocytes (Barry et al.,
1998). To sum up, these data suggest that EEVs shed from the
activated endothelial cells in MS patients promote the migra-
tion of monocytes and lymphocytes through the BBB and assist
with the formation of demyelinating lesions. A validation of this
hypothesis was performed in an elegant experiment carried by
Jimenez et al. (2005): they investigated the transendothelial migra-
tion of monocytes using the MVEC model, adding plasma from
remitting or relapsing MS patients and controls, and found that
only the plasma from patients in relapse significantly promoted
transendothelial migration. See Figure 2 for a graphical summary
of this paragraph.
Shedding new light on the role of EVs, a few recent studies
have investigated EVs in the animal model of MS called exper-
imental autoimmune encephalitis (EAE). The first published by
Gatson et al. (2011) analyzed EVs (exosomes in this case) in late
pregnant compared to virgin EAE mice. Results showed that EVs
derived from serum of mice in late pregnancy were more numer-
ous than those isolated from virgin mice. The proliferation of
T-cells derived from splenocytes was also explored in the presence
of whole serum, purified EVs, and EV-depleted serum. The three
phases derived from pregnant animals were significantly more
suppressive of T-cell proliferation than EVs from virgin animals
or cells cultured without any EVs. On the basis of these findings,
authors concluded that EVs are responsible for immune modu-
lation during EAE pregnancy. A further study by the same group
analyzed this immune modulation showing a reduction in IFN-
gamma production and expression of Tbet (Th1 transcription
factor) in T cells exposed to pregnancy-derived EVs. In addition,
these researchers demonstrated the effect of pregnancy-derived
EVs on migration to lesion areas in EAE of oligodendrocyte pre-
cursor cells and their maturation (Williams et al., 2013). This
is the first publication that denoted a protective role of EVs in
MS/EAE.
Verderio et al. (2012) identified other EV origins analyzing in
depth CSF from humans and mice, both healthy and MS/EAE. Sev-
eral types of brain cell including neurons, astrocytes, and resident
microglial cells give rise to EVs. Peripheral macrophages are virtu-
ally absent in healthy brain parenchyma suggesting that myeloid
EVs obtained in CSF are derived from resident microglia in the
normal brain. This group also revealed that microglia store and
release IL1-beta and MHC-II suggesting that the EVs produced
from reactive myeloid cells may propagate neuroinflammation and
provide an efficient route for rapid dissemination and presentation
of antigens.
Regarding platelet-derived EVs (PEVs) in MS, P-selectin was
observed on PEVs capable of binding to PSGL-1 and PECAM-1
from lymphocytes by increasing the expression of integrins such
as α4β1 (VLA-4), promoting the binding of these cells to the
endothelium (Sheremata et al., 2008). Interestingly, this epitope
is the target of natalizumab, one of the recent therapies approved
for relapsing–remitting MS.
All this evidence supports the idea that EVs are involved in MS
playing a pathological role, acting as immunomodulator agents in
the disruption of the BBB and the propagation of inflammation
of the parenchyma but that, on the other hand, they contribute to
the repair of demyelinating lesions.
ARE EVs RELIABLE BIOMARKERS IN MS?
As stated above, the association between EV concentration and the
pathological condition of MS patients is clearly established. The
next challenge is to develop the application of EVs as useful bio-
markers: as well as providing relevant information, they are easy
to process at a low cost and hence their use could be extended
to large study populations. However, clearly, the adoption of EVs
as biomarkers needs to be based on an objective assessment of
their diagnostic and monitoring potential for the disease in ques-
tion. In the case of MS, EV measurements must be correlated
with the clinical judgment of the neurologist, established scores,
and the results of other complementary tests such as MRI. Sev-
eral studies discussed in the following paragraphs have addressed
these issues but it should be noted that the results are mixed,
sometimes inconsistent, depending on the type of EV (MV, MP,
or exosomes), their cell origin, methods employed, and analysis
performed.
EV CONCENTRATION AND CLINICAL STATUS
A relationship between EV counts in plasma and MS status was
first proposed by Minagar et al. (2001) more than a decade
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FIGURE 2 | Pathogenic roles of EV in MS. EVs are involved in the
transendothelial cell migration of lymphocytes and monocytes and the spread
of neuroinflammation. Metalloproteases carried by EEVs promote BBB
disruption. The release of proinflammatory cytokines from lymphocytes
augments adhesion molecules on endothelial cells facilitating cell adhesion.
In the CNS compartment, microglia play a key role in propagation of
neuroinflammation shedding MEVs containing IL1-b and MHC-II. BBB,
blood–brain barrier; CNS, central nervous system; AA, arachidonic acid; EEV,
endothelial-derived extracellular vesicle; LEV, leukocyte-derived extracellular
vesicle; MEV, microglia-derived extracellular vesicle.
ago. Their results revealed that CD51+ EEV concentrations were
higher in relapse and remission, while those of CD31+ EEVs were
only higher during relapse, compared to healthy controls. They
proposed that the increase in CD51+ EEVs was related to chronic
inflammation owing to endothelial erosion with subendothelial
matrix exposure, and that CD31+ EEVs reflect acute endothelial
damage. This was tested in vitro, and the results were only partially
reproduced. Together the findings pointed to the existence of fac-
tors present in the plasma of MS patients but not in the in vitro
model, such as activated leukocytes present during exacerbations,
which were able to regulate the release of EEVs. Authors also
described a concordance between CD31+ EEV counts and gad+
MRI findings. They claimed that these vesicles were as sensitive as
gad+ MRI for detecting disease activity, and also that a decrease
in vesicle count could precede a negativization of MRI findings.
However, this was criticized for being a premature speculation and
not supported by sufficient evidence (Larkin, 2001).
In the same line of research, 3 years later Jy et al. (2004) explored
whether CD54+ and CD62E+EEVs bound leukocytes in vitro and
in whole blood from MS patients and controls. Their main conclu-
sion was that CD54+ EEVs form complexes with monocytes in a
TNF-alpha environment and also activated them. CD62E+ EEV–
monocyte complexes were more numerous during exacerbations
than in remission while the number of CD54+ EEV–monocyte
complexes remained unchanged, suggesting that the former would
be a better marker for monitoring MS. Authors reported that the
measurement of both EEV–monocyte complexes together as a sin-
gle EEV–monocyte complex fraction appeared to be more sensitive
to MS exacerbation than gad+MRI and even more sensitive than
the CD31+ EEV analysis studied in their previous work. Finally,
free EEVs (unbound to cells) bearing CD62E allowed better dis-
crimination of disease activity (relapsing vs. remitting patients)
than CD54+ EEVs, but not compared to the previously reported
CD31+ EEVs.
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Conversely a year later, Jimenez et al. explored free CD54+ and
CD62E+ EEVs in vitro reporting an increase in both markers dur-
ing relapse and normal values similar to control in remission. Ana-
lyzing EEVs from relapsing patients only, CD54+ and CD62E+
phenotypes were present in significantly higher numbers than
CD31+ EEVs, indicating that they were more sensitive (in vitro)
for identifying MS status (Jimenez et al., 2005). As stated by Witwer
et al. (2013), EV studies are highly heterogeneous, this being attrib-
utable to the lack of standardized methods. Possibly, this underlies
the mixed results described here, particularly with respect to the
earlier work by Jy and colleagues.
Besides EEVs, other EVs have been explored including those
derived from platelets, leukocytes, and monocytes. Platelet acti-
vation in patients with MS may be secondary to endothelial
damage (Sheremata et al., 2008). CD62P (P-selectin) levels have
been shown to be higher in MS patients than controls. Twofold
higher CD41+ PEV counts were found in MS patients compared
to controls, these vesicles showing properties as anticoagulants
(Sheremata et al., 2008). Our group also demonstrated a significant
difference in CD61+ PEV, CD45+ LEV, and CD14+MEV counts
in samples from MS patients compared to those from healthy
controls (Sáenz-Cuesta et al., 2014). Moreover, the PEV count
was found to be higher in untreated MS patients than controls.
Relapsing–remitting patients had the highest counts for the three
subtypes of EVs while secondary progressive patients were found
to have similar numbers to those in healthy controls. We hypoth-
esized that EVs reflect disease status with more being shed during
inflammatory periods and numbers returning to baseline during
chronic progressive degeneration. Another approach to monitor-
ing the progression of the disease is to assess patient’s disability
using the Expanded Disability Status Scale. Our group found no
relationship, however, between EV counts and scores on this scale,
and nor were the counts related to disease duration or patients’age.
In human CSF, the numbers of EVs have also been seen to be
higher in patients than controls (Verderio et al., 2012). Among
patients, the acute phase was associated with higher numbers of
MEVs than stable or chronic phases. In addition, MEVs counts cor-
related linearly with gad+MRI images. In line with this, the con-
centration of MEVs obtained from CSF of EAE mice reflects the
course and severity of EAE. The absolute numbers of MEVs were
closely associated with the course of the disease, peaking at onset
and during clinical relapses, and decreasing in the chronic phase
of the disease or stable phase. In this work, authors also explored
the potential of MEVs as a possible biomarker in MS plotting
ROC curves. Specifically, based on ROC analysis, they obtained
a sensitivity of 85% and specificity of 100% for distinguishing
clinically isolated syndrome patients from healthy controls, and a
sensitivity of 82% and specificity of 82% for differentiating stable
(relapse-free patients) from relapsing MS patients.
EVs AND MS THERAPY
Current MS therapy is based on the modulation of the immune
system with a wide range of drugs. In some cases, including
IFN-beta, natalizumab, and fingolimod, the effect of the drug
on EVs has been explored. However, there are several new drugs,
already approved (teriflunomide, alemtuzumab, BG-12) or in the
final phases of testing (laquinimod, alemtuzumab, ocrelizumab),
in which the potential modulation of EVs has not yet been
investigated.
IFN-beta has antiviral and immunoregulatory activity medi-
ated by its interaction with specific cell receptors on the surface
of human cells. The precise mechanism of action in MS is still
under investigation. So far, it is known that IFN-beta reduces the
permeability of the BBB inhibiting leukocyte migration to the
CNS (Calabresi et al., 1997) possibly interfering with endothe-
lial adhesion, shifting the cytokine balance from Th1 to Th2, and
increasing the expression of occludin at endothelial tight junctions
(Dhib-Jalbut et al., 1996).
The effect of IFN-beta 1b on EVs was first explored by Jimenez
et al. (2005) who observed an inhibitory effect on EEV pro-
duction in vitro from MVEC culture adding plasma from MS
patients, both in remission and relapse. Moreover, it was shown
that monocyte–EEV complex formation and transendothelial
migration are impaired after IFN-beta 1b exposure.
A first prospective study in a cohort with relapsing–remitting
MS revealed a reduction in the numbers of CD31+EEVs in plasma
from week 12 of treatment with IFN-beta 1a (Sheremata et al.,
2006). Conversely, no correlation was found with MRI, though
there was insufficient data to draw definitive conclusions. Find-
ings in a second cohort treated with high doses of INF-beta 1a
and followed-up for a year suggest that CD54+ EEV number rep-
resents a more sensitive marker of treatment effect than CD31+
or CD146+ EEV numbers, while results showed a correlation of
both CD31+ and CD54+ EEVs with T1-weighted MRI findings
(the relation with CD146+ EEV failing to reach statistical sig-
nificance) (Lowery-Nordberg et al., 2011). Authors speculate that
the decrease they observed in plasma vesicles with IFN-beta ther-
apy reflects a reduced interaction between CD4+ T-cells and the
endothelium and subsequently less migration of the cells through
a restored BBB.
Another immunomodulating drug approved (in 2006) for MS
treatment is natalizumab, a recombinant humanized monoclonal
antibody. A selective adhesion molecule inhibitor, binds to the
alpha-4 subunit of human integrins profusely expressed on the
surface of all leukocytes except neutrophils. In particular, it binds
to alpha-4-beta-1 integrin, blocking the interaction with its ana-
log receptor, the vascular cell adhesion molecule-1 (VCAM-1).
Disruption of these molecular interactions prevents mononuclear
leukocyte migration across the endothelium into the inflamed
parenchymal tissue (Selewski et al., 2010). In a recent study ana-
lyzing plasma PEVs, LEVs, and MEVs, our group found higher
counts of all three EV subtypes in IFN-beta and natalizumab-
treated than untreated patients (Sáenz-Cuesta et al., 2014). No
significant differences were found between the two therapies. A
plausible hypothesis specifically for the rise in LEV number in
natalizumab-treated patients is that blockage of leukocyte entry
into the CNS would result in increase in the number of leukocytes
in the blood compartment and, in turn, of LEVs in particular.
The rise observed in the other two EV subtypes is, however, less
well-understood.
Fingolimod is a new oral immunomodulator drug approved
for the relapsing–remitting form of MS. It binds and induces
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downregulation of the sphingosine 1 phosphate receptors present
in lymphocytes regulating their egress from lymphoid tissues into
the circulation. In that way, the drug reduces autoaggressive lym-
phocyte infiltration into the CNS (Chun and Hartung, 2010). Acid
sphingomyelinase (aSMase) is inhibited by fingolimod (Dawson
and Qin, 2011) and this enzyme controls EV production. These
observations led Verderio et al. to theorize that using fingolimod
could inhibit MEV shedding from reactive microglia and also
macrophage infiltration into the CNS. Their experiments in an
EAE model confirmed that MEV numbers decreased to base-
line levels in the CSF with the administration of fingolimod. In
mice, symptom scores and MEV counts were correlated during
fingolimod treatment. Hence, a novel effect of fingolimod was
postulated, namely, that it limits the spreading of the inflamma-
tory signal by impairment of MEV production (Verderio et al.,
2012). Despite these conclusions, there have so far been no
reports evaluating the effect of fingolimod on EVs in humans,
probably because it has only relatively recently become available
commercially.
Apart from being biomarker for treatment response, it has been
proposed that engineered EVs be loaded and used to deliver exoge-
nous compounds for therapeutic purposes, raising the prospect of
a novel clinical application for EVs. Preliminary studies with exo-
somes have been carried out in some types of cancer (Kosaka et al.,
2013); however, more research is required before this approach
can be used in clinical practice as a complementary therapy. Par-
ticularly in MS, a recently published study explored the ability
of exosomes packed with microRNA to increase baseline myeli-
nation, reduce oxidative stress, and improve remyelination (Pusic
et al., 2014). The results showed a significant increase in myeli-
nation in hippocampal slice cultures. Nevertheless, the effects
of this therapeutic approach need to be investigated further,
first in an animal model such as EAE and later in a clinical
trial.
CONCLUDING REMARKS
Extracellular vesicles play important roles in the development
of MS, in particular activating cells during relapses, leading to
migration through the BBB, and spreading inflammation in CNS
tissue. On the other hand, a protective effect of EVs has been
described with the induction of maturation and migration of
oligodendrocyte precursor cells.
Regarding the application of EV research findings to daily clin-
ical practice, it is not yet possible to propose EVs as a specific
biomarker for MS due to no compounds having been sufficiently
closely linked to the disease. Nevertheless, there is evidence that
they reflect disease progression. Particularly, EEVs, PEVs, and
MEVs appear to be the most accurate markers. What is more,
the effects of treatments seem to be reflected in EV counts.
We consider it likely that new carefully designed studies with
longer follow-up periods will allow us to confirm the involve-
ment of EVs suggested by our current knowledge and open future
applications.
Finally, there is an urgent need for consensus guided by the
new scientific societies for EVs to standardize the methodolo-
gies and instruments used, in the analysis of EVs with potential
applications in clinical practice, and thereby make it possible to
obtain comparable results.
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